1. Scrip
  2. >>Business
  3. >>Earnings

Cimzia Keeps Raking In The Cash As UCB Waits For New Products Impact

TNF Blocker Peaks Early

 
• By Kevin Grogan

The Belgian group’s older products helped push 2022 revenues to the top of their guidance range as the peak sales forecast for the new epilepsy drug Fintepla is set at €800m.

UCB flag
• Source: UCB

As it patiently waits to finally get US approval for potential autoimmune disease blockbuster Bimzelx, UCB S.A. has been highlighting the continued strong growth of its less high-profile drug in the space, the TNF blocker, Cimzia.

The Belgian drugmaker has issued a financial update saying that it expects to "land at the upper end of the range" of its guidance for 2022 which targeted revenues of €5.3bn-$5.4bn

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

More from Business

Accelerated Approval May Be Out Of Reach For PTC’s Huntington’s Drug

 
• By Joseph Haas

PTC said its updated Phase II data for PTC 518 met the primary endpoint of Huntingtin’s protein reduction, but analysts said there isn’t clear correlation with clinical benefit.

Finance Watch: Unity Lays Off All Employees As It Evaluates Alternatives

 
• By Mandy Jackson

Restructuring Edition: Unity unveiled more Phase IIb data for lead asset UBX1325 along with plans to shed its workforce while seeking a partner for it and other drugs. Also, Ono is consolidating US employees at one site, Entrada is cutting its workforce by 20% and other recent strategic shifts.

Pharma Predicts Modest Impact From Tariffs, But It Depends On What Comes Next

 
• By Jessica Merrill

Drugmakers aren’t expecting a big financial hit from tariffs for now, but a report commissioned by PhRMA suggests the cost of pharma-sector tariffs could be steep.